First milestone payment for ADC-1013

Alligator Bioscience receives milestone payment from the CD40 Agonistic Immuno-Oncology Antibody ADC-1013 project with Johnson & Johnson Innovation

Alligator Bioscience AB is a privately held Swedish biotech company developing immuno-oncology antibodies for directed immunotherapy of cancer. Alligator granted Johnson & Johnson an exclusive, worldwide license to Alligator’s clinical candidate ADC-1013 in an agreement entered in August 2015.

According to this agreement, Janssen will be responsible for developing ADC-1013 and will assume responsibility for the clinical studies once the ongoing, by Alligator sponsored Phase I dose escalation study is completed.

There has now been an amendment of the protocol to expand the current Phase I Clinical Study to include a systemic administration arm. This entitles Alligator to a milestone payment of USD 5M. 

Separately Janssen and Alligator have also entered a research collaboration to broaden the pre-clinical data package of ADC-1013. Janssen will reimburse Alligator for 2.5 FTEs and running expenses under this agreement.

“It is very encouraging for the ADC-1013 project and the ongoing Phase I studies that the trials are progressing extremely well and are being expanded by a systemic administration arm. This will give us and our partner Janssen important information for the future development of ADC-1013” said Per Norlén CEO at Alligator Bioscience.

For further information, please contact:

Per Norlén, CEO Alligator Bioscience AB, Office number: +46 2864280

About ADC-1013

ADC-1013 is an agonistic fully human monoclonal antibody targeting CD40, an immuno-stimulatory receptor found on antigen-presenting cells such as dendritic cells. Stimulation of CD40 on dendritic cells initiates a process leading to a dramatic increase in T effector cells attacking the tumor. In addition, a tumor-specific memory is established, leading to long-term immunity to the cancer.

About Alligator

Alligator Bioscience discovers and develops innovative antibody based immunotherapies for the treatment of cancer. Alligator Drug Discovery and Development span from early research phases up to proof of concept phase I/II clinical studies in cancer patients. In the discovery of novel antibody based drugs, Alligator uses its proprietary technology platforms FIND® and ALLIGATOR-GOLD®. FIND® (Fragment INduced Diversity) is an antibody optimization technology based on single-stranded DNA allowing generation of antibodies with significant clinical benefits. ALLIGATOR-GOLD® is a synthetic library containing several billion distinct fully human antibodies.  

Alligator Bioscience AB, founded in 2001, is a privately held company with around 200 shareholders, located at Medicon Village, Lund, Sweden.

www.alligatorbioscience.com

About Us

Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s growing pipeline includes lead clinical and pre-clinical drug candidates (ADC-1013, ATOR-1015, ATOR-1017 and ALG.APV-527) and novel research candidates. ADC-1013 (JNJ-64457107) is licensed to Janssen Biotech, Inc., part of J&J, for global development and commercialization. Alligator’s shares are listed on Nasdaq Stockholm (ATORX). The Company is headquartered in Lund, Sweden, and has approximately 45 employees.

Subscribe

Documents & Links